Abstract
Background and Aims We aimed to ascertain the feasibility and safety of NA cessation, the status of patients after cessation, and the predictive factors for relapse and subsequent retreatment. Methods A total of 92 patients were enrolled in this prospective study. Patients were monitored every month for the first 3 months after cessation and every 3 months thereafter. Results Sixty-two patients finished 48 weeks of follow-up. None died or developed liver failure, cirrhosis, or HCC. The 62 patients could be divided into 4 categories according to the 48-week clinical development of relapse. Virologic relapses occurred in 39 (62.9%) patients, with 72.7% occurring in the first 24 weeks in origin HBeAg positive patients and 82.4% in the first 12 weeks in origin HBeAg negative patients. Age (OR = 1.06, 95% CI = 1.02–1.10; p = 0.003), the HBsAg level (OR = 2.21, 95% CI = 1.47–3.32; p < 0.001), and positive origin HBeAg status (OR = 0.32, 95% CI = 0.14–0.74; p = 0.008) were predictive factors to virologic relapse. HBV DNA level (OR = 1.34, 95% CI = 1.13–1.58; p < 0.001) was predictive factor to retreatment. Conclusions NA cessation is safe under supervision. Age, HBsAg level, and origin HBeAg status can be predictive factors for virologic relapse. The study was submitted to ClinicalTrials.gov Protocol Registration and Results System with the assigned NCT ID NCT02883647.
Highlights
Chronic hepatitis B virus (HBV) infection is a major health problem, as approximately 240 million people are infected worldwide [1]
Nucleos(t)ide analogues (NA) have been developed to control HBV [2], and they can strongly inhibit reverse transcriptase to suppress the HBV DNA levels but cannot erase covalently closed circular DNA, as it integrates into the genome in the nuclei of the host hepatocytes [3]
All patients were treated with nucleos(t)ide analogues, such as entecavir (ETV), telbivudine (LDT), lamivudine (LAM), adefovir dipivoxil (ADV), or a combination of LAM and ADV
Summary
Chronic hepatitis B virus (HBV) infection is a major health problem, as approximately 240 million people are infected worldwide [1]. Long-term NA therapy can control chronic hepatitis B, but several problems remain. We aimed to ascertain the feasibility and safety of NA cessation, the status of patients after cessation, and the predictive factors for relapse and subsequent retreatment. The 62 patients could be divided into 4 categories according to the 48-week clinical development of relapse. Age (OR = 1.06, 95% CI = 1.02–1.10; p = 0.003), the HBsAg level (OR = 2.21, 95% CI = 1.47–3.32; p < 0.001), and positive origin HBeAg status (OR = 0.32, 95% CI = 0.14–0.74; p = 0.008) were predictive factors to virologic relapse. HBV DNA level (OR = 1.34, 95% CI = 1.13–1.58; p < 0.001) was predictive factor to retreatment. HBsAg level, and origin HBeAg status can be predictive factors for virologic relapse. The study was submitted to ClinicalTrials.gov Protocol Registration and Results System with the assigned NCT ID NCT02883647
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Canadian Journal of Gastroenterology and Hepatology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
